APLN and Alzheimer disease: Apelin treatment improved AD-MSCs survival in vivo. In Sham + AD-MSCs + apelin and AD-MSCs + apelin group, donor AD-MSCs exhibited significantly enhanced survival, as evidenced by a remarkably higher BLI signal intensity than their respective non-apelin-treated groups on POD35 (Fig. 3B).